Swiss medtech company Bloom Diagnostics enters UK market and joins British pharmaceutical conference

Bloom Diagnostics to present at The Pharmacy Show in Birmingham shortly after its entrance into the UK market

UNITED KINGDOM (UK): On October 16th and 17th 2022, Bloom Diagnostics will join The Pharmacy Show in Birmingham. This will be the company’s first time attending this event. 

At The Pharmacy Show, Dr Christina Ornauer, Chief Medical Officer at Bloom Diagnostics, will be giving a speech on the current landscape of the healthcare environment in the UK, focusing on the evolution of point-of-care digital testing and how it can be successfully implemented in pharmacies. She will also highlight Bloom Diagnostics’ role in shaping the future of smart diagnostics, presenting how the company’s technology addresses some of the pressing challenges in the pharmacy environment. Learnings from patient interactions, their test results, and how the knowledge can be leveraged in pharmacy settings will also be shared.

Attending The Pharmacy Show aligns with Bloom’s expansion into the UK, which began earlier this year. Tom Kupper, Co-founder and Chief Product Officer (CPO) at Bloom Diagnostics commented that “Our recent entry into the UK market has been significant for us in our journey to expand globally. We can't wait to have many interested potential Bloom partners get their hands on the Bloom System and test it themselves at our booth.”

Attendees at The Pharmacy Show will also have the opportunity to learn more about the products offered by Bloom Diagnostics. These include the innovative Bloom System, consisting of the Bloom Lab and a variety of blood tests, which can be used to evaluate different biomarkers. While Bloom Diagnostics constantly works to expand its portfolio of tests, its customers are currently offered the Bloom Ferritin, Thyroid, Inflammation and Kidney Tests. Angelica Kohlmann, MD PhD, Co-founder and Chairperson at Bloom Diagnostics, comments that “The Pharmacy Show offers the best possible platform to present Bloom and its digital blood testing products to the professional public.”

Bloom Diagnostics was founded in 2018 by Dr. Angelica Kohlmann and Tom Kupper. In 2020 and 2021 the company closed funding rounds to further strengthen R&D and drive expansion throughout Europe. Bloom Diagnostics’ early investors include Speedinvest from Austria and the Canadian Walter Group. Bloom Diagnostics aims to rapidly add meaningful new features to its range of capabilities to accelerate the pace of clinical discoveries and, ultimately, the development of new therapies.